Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)

Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ) - PROVID-CAPNETZ

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022871

Enrollment

400

Registered

2020-10-01

Start date

2020-10-13

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 19 (COVID-19) U07.1 J12 J13 J14 J15 J16 J17 J18

Interventions

Group 1: Patients with positive detection of the SARS-CoV-2 virus (Coronavirus disease-19 (COVID-19)): Development of a database and biomaterial bank for research of the COVID-19 disease Examinations

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria (PROVID-CAPNETZ): • Age = 18 • Radiological proof of infiltrate (primarily chest x-ray or CT) with positive detection of SARS-CoV-2-virus or • with no proven infiltrate with positive detection of SARS-CoV-2-virus • Informed consent signed

Exclusion criteria

Exclusion criteria: Exclusion criteria (PROVID-CAPNETZ): • Newly diagnosed, active pulmonary tuberculosis within the last 2 months • Simultaneous participation in PROVID-PROGRESS or PROVID-CAPSyS cohort • Participation of the patient in PROVID-PROGRESS or PROVID-CAPSyS cohort at an earlier point in time

Design outcomes

Primary

Measure	Time frame
Aims: Characterize the host- and virusdependent mechanisms associated with the clinical appearance of COVID-19 to improve patient care through advances in risk stratification and clinical management.	—

Secondary

Measure	Time frame
Aims: Checking the following hypotheses: 1) Host factors (transcriptional response/RNA, proteins, antibodies) determine the severity and / or course of COVID-19. 2) Molecular and clinical determinants of COVID-19 differ from those that have been deciphered in other forms of pneumonia and they can be used as molecular predictors of disease progression. 3) Specific molecular markers of severe disease can be tested as therapeutic targets for COVID-19. 4) In addition to presently pursued antivirals and immunomodulators, the stabilization of the pulmonary barrier function could establish a third line for an effective therapy.	—

Measure

Time frame

Aims: Checking the following hypotheses: 1) Host factors (transcriptional response/RNA, proteins, antibodies) determine the severity and / or course of COVID-19. 2) Molecular and clinical determinants of COVID-19 differ from those that have been deciphered in other forms of pneumonia and they can be used as molecular predictors of disease progression. 3) Specific molecular markers of severe disease can be tested as therapeutic targets for COVID-19. 4) In addition to presently pursued antivirals and immunomodulators, the stabilization of the pulmonary barrier function could establish a third line for an effective therapy.

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026